Beacon NewsFlashes – May 14, 2010

Myeloma Experts From Ohio State University To Field Questions At The Beacon Forums Next Week – As a way of giving multiple myeloma patients an opportunity to get expert answers to their myeloma-related questions, The Myeloma Beacon has arranged for physicians from The Ohio State University’s Myeloma Clinic to answer medical questions posted to the Beacon forums during the upcoming week. The center has a number of young, enthusiastic myeloma specialists who are eager to answer forum readers’ questions. One of the experts, Dr. Craig Hofmeister, has already provided answers to a number of forum questions. Readers are encouraged to begin posting their questions to the forums.
Boehringer Ingelheim And Micromet Announce Cooperation For Experimental Multiple Myeloma Treatment – Boehringer Ingelheim and Micromet announced last week that they will collaborate on the development of BiTE antibodies for the treatment of multiple myeloma. BiTE antibodies, which were discovered by Micromet, target the body’s immune system toward tumor cells. The two companies will conduct pre-clinical studies together. Boehringer Ingelheim will be responsible for the clinical development of the treatment. For more information, please see the Boehringer Ingelheim press release.
Celebrity Michael McKean Wins $1 Million On Jeopardy! For International Myeloma Foundation – Michael McKean, a film and television show actor, writer, and director, was the champion of last week’s Jeopardy! celebrity tournament. McKean donated the grand prize of $1 million to the International Myeloma Foundation (IMF) to be used for patient and family education programs as well as multiple myeloma research. For more information, please see the IMF press release.
Related Articles:
- Diet May Affect Risk Of Developing MGUS And Risk Of MGUS Progressing To Multiple Myeloma
- Selective Digestive Decontamination May Reduce Risk of Infection In Myeloma Patients Undergoing Autologous Stem Cell Transplants
- Number And Type Of Stem Cell Transplants Carried Out Each Year For Multiple Myeloma Vary Markedly Across U.S. Cancer Centers
- Dr. Christoph Driessen On Nelfinavir In The Treatment Of Multiple Myeloma
- ASCO 2018 Update – Expert Perspectives On The Key Multiple Myeloma-Related Oral Presentations
Dear Beacon-Team, I know that this Bite-Antibody-article is from last year. But I try to ask you something about this: Do you know, how long such a development will need? Could one estimate, how long (of course we could not know if it is successfull) the road from preclincical discovery and phase II-trials will be ordinarily? Thank you, Karen
Karen,
The FDA provides information about each phase of drug development, including how long it typically takes, how much it typically costs, and the likelihood that a drug candidate will successfully pass that phase. As you'll see, preclinical development can take 1 to 6 years, and then clinical development can take 6 to 11 years. http://www.fdareview.org/approval_process.shtml
Progress toward fundraising goal
for all of 2020:
15%
For more information, see the Beacon's
"2020 Fundraising: Goals And Updates" page